The dogma that antineoplastic treatments kill tumour cells by damaging essential biological
functions has been countered by the notion that treatment itself initiates a programmed …

Heterogeneity in the clinical behavior of patients with chronic lymphocytic leukemia (CLL)
makes it difficult for physicians to accurately identify which patients may benefit from an early …

This is the third volume in the new World Health Organization series on histological and
genetic typing of tumours. Tumours of the haematopoietic and lymphoid tissues are covered …

Purpose We conducted a randomized trial to evaluate the efficacy and safety of intravenous
alemtuzumab compared with chlorambucil in first-line treatment of chronic lymphocytic …

Recent studies have suggested that rituximab has clinical activity and modulates
antiapoptotic proteins associated with drug resistance in chronic lymphocytic leukemia …

The presence of p53 mutation or deletion predicts for poor response to conventional therapy
in chronic lymphocytic leukemia (CLL). We sought to determine whether the humanized anti …

Purpose Genomic features including unmutated immunoglobulin variable region heavy
chain (IgVH) genes, del (11q22. 3), del (17p13. 1), and p53 mutations have been reported to …

Purpose We reported encouraging early results of allogeneic hematopoietic cell
transplantation (HCT) after nonmyeloablative conditioning in 64 patients who had advanced …

Background Patients with the inherited disorder ataxia telangiectasia (AT) have an
increased susceptibility to lymphoid malignancies. In these patients mutations affect both …

Approximately 5% of B-cell chronic lymphocytic leukemia (B-CLL) patients develop a
secondary aggressive lymphoma, usually of diffuse large B-cell type (DLBCL), termed …